Liquidia
Liquidia Technologies, a US-based biopharmaceutical firm, uses proprietary PRINT tech for developing human therapeutics.
Founded
2004Liquidia Technologies, a US-based biopharmaceutical firm, uses proprietary PRINT tech for developing human therapeutics.
Liquidia Technologies, founded in Morrisville, United States, is a late-stage clinical biopharmaceutical company dedicated to developing and commercializing human therapeutics. Utilizing their proprietary PRINT technology, Liquidia precisely engineers uniform drug particles to enhance the safety, efficacy, and performance of various therapies. The company's current focus includes developing treatments for pulmonary arterial hypertension (PAH) and pulmonary arterial hypertension associated with interstitial lung disease (PH-ILD).
Notable figures affiliated with Liquidia include its leadership team and board members who bring extensive experience in biopharmaceutical development and commercialization. The company has attracted significant investment from leading venture capital firms and strategic partners. Key achievements include advancing their product candidates through clinical trials and demonstrating the potential of PRINT technology to revolutionize drug delivery. Liquidia's impact lies in its commitment to improving patient outcomes and addressing unmet medical needs in the field of pulmonary diseases.
Companies similar to Liquidia include Lung Biotechnology, Liquid Biotech, United Therapeutics and Pulmatrix.
Liquidia was founded in 2004.
Liquidia's headquarters is located in Morrisville, NC, US.
Liquidia's most recent funding round was for $75M (USD) in January 2024.
As of Jan 4, 2024, Liquidia has raised a total of $415.9M (USD).
Liquidia has 75 employees as of Feb 5, 2024.
United Therapeutics
